Corvidia Therapeutics
Biotechnology company that developed ziltivekimab, an anti-IL-6 antibody for cardiovascular and kidney diseases. Acquired by Novo Nordisk in 2020 for up to $2.1 billion.
Website
https://www.corvidiatx.comLocation
Waltham, Massachusetts, USA
Founded
2015
Investors
2
Categories
biotech, cardiovascular, therapeutics, inflammation, kidney-disease
Notes
Corvidia Therapeutics was a biotechnology company focused on developing anti-inflammatory therapies for cardiovascular and kidney diseases. The company's lead program, ziltivekimab, is a monoclonal antibody targeting IL-6 (interleukin-6) to reduce inflammation in patients with chronic kidney disease and cardiovascular risk.
In August 2020, Novo Nordisk acquired Corvidia Therapeutics for up to $2.1 billion to expand its cardiovascular disease pipeline. Ziltivekimab is now being developed by Novo Nordisk in Phase 3 clinical trials.
Team (Pre-Acquisition)
- Marc Bhatt - Former Chief Executive Officer
Additional Research Findings
- Acquired by Novo Nordisk in August 2020 for up to $2.1 billion
- Ziltivekimab: anti-IL-6 antibody for inflammation
- Focus on cardiovascular and kidney disease
- Portfolio company of Sofinnova Partners
- Now part of Novo Nordisk pipeline
- Phase 3 clinical trials ongoing (ZEUS-CV, ZEUS-CKD)
- Waltham, Massachusetts headquarters (pre-acquisition)
- Addressing inflammatory component of cardiovascular disease
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |